Annual Report Highlights Strong 2025 Profitability, $1.07B Revenue, and Key Pipeline Updates Amidst EU Regulatory Setback

summarizeSummary

Acadia Pharmaceuticals reported strong 2025 financial results, achieving cumulative profitability and over $1 billion in revenue, but faces a significant setback with a negative EU regulatory vote for DAYBUE.

check_boxKey Events

• Achieved Cumulative Profitability

  The company achieved cumulative three-year profitability in 2025, leading to the recognition of $249.9 million in deferred tax assets, a significant improvement in financial health.

• Strong 2025 Revenue Growth

  Net product sales for 2025 totaled $1,071.5 million, up from $957.8 million in 2024, driven by increased sales of both NUPLAZID ($680.1M) and DAYBUE ($391.4M).

• EU Regulatory Setback for DAYBUE

  In January 2026, the EMA's CHMP issued a negative trend vote on the marketing authorization application for trofinetide (DAYBUE) for Rett syndrome in Europe. The company intends to request a re-examination.

• DAYBUE STIX and International Approvals

  The FDA approved DAYBUE STIX (powder formulation) in December 2025, with a broader launch planned for Q2 2026. DAYBUE also received marketing authorization in Israel (December 2025) and Canada (October 2024).

auto_awesomeAnalysis

Acadia Pharmaceuticals' annual report for 2025 reveals a significant financial turnaround, achieving cumulative three-year profitability and recognizing $249.9 million in deferred tax assets. This marks a substantial improvement in the company's financial health. Net product sales exceeded $1 billion, driven by strong performance from both NUPLAZID and DAYBUE. However, the company faces a notable setback with a negative trend vote from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding the marketing authorization application for trofinetide (DAYBUE) in Europe. While the company plans to request a re-examination, this introduces uncertainty for European market expansion. Additionally, the Phase 3 study for ACP-101 in Prader-Willi Syndrome failed, leading to discontinuation of that program. Investors should weigh the strong financial performance and pipeline advancements against the significant European regulatory challenge and the impact of higher Medicare rebates on NUPLAZID sales.